• Net sales grew 4% (cc[1], +10% USD) mainly driven by:
  • Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide
  • Cosentyx was USD 580 million, +35% (cc) with strong growth in all indications and expanded access
  • Oncology returned to growth (+6% cc) driven by Promacta/Revolade, Tafinlar + Mekinist, Jakavi and recent launches
• Core[1] operating income grew 4% (cc, +11% USD) as higher sales helped support growth and launch investments; Core EPS of USD 1.28, …

• Deal includes reSET^®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine 
• Combines Sandoz expertise in launching / commercializing treatments with Pear’s expertise in developing prescription digital therapeutics 
• Sandoz and Novartis continue to embrace emerging digital technologies to enhance R&D and deliver better outcomes for patients

…

• Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare
• Publication, which coincides with World Health Day 2018, outlines plans for expanded competition to “reimagine access to healthcare”
• Upcoming HACk will draw strongly on learnings of past year; publication summarizes progress to date on three winning 2017 projects

Holzkirchen, April 7, 2018 – Sandoz today announces its continued commitment to improving …